Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPD489 (Vyvanse) in adolescents with ADHD
NCT01274221Phase 3Withdrawn
- Sponsor
- Takeda
- Start
- Mar 2011
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Takeda. Planned start Mar 2011; status: withdrawn.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01274221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01274221.